바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.70 No.3
Citation Share

A Case of Prothionamide Induced Hepatitis on Patient with Multi-Drug Resistant Pulmonary Tuberculosis

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2011, v.70 no.3, pp.251-256


















& (2011). A Case of Prothionamide Induced Hepatitis on Patient with Multi-Drug Resistant Pulmonary Tuberculosis. Tuberculosis & Respiratory Diseases, 70(3), 251-256.
  • Downloaded
  • Viewed
PDF Download

Abstract

The prevalence of multi-drug resistant tuberculosis (MDR-TB), which is resistant to isoniazid and rifampin, has been increasing in Korea. And the side effects of 2nd line anti-tuberculosis medications, including drug-induced hepatitis, are well known. Although prothionamide (PTH) is one of the most useful anti-TB medications and although TB medication-induced acute hepatitis is a severe complication, there are only a few published case reports about prothionamide induced hepatitis. In this case report, a 22 year old male was diagnosed with pulmonary MDR-TB and was administered 2nd line anti-TB mediations, including PTH. Afterwards, he had a spiking fever and his liver enzymes were more than 5 times greater than the upper limit of the normal range. He was then diagnosed with drug-induced hepatitis by liver biopsy. His symptoms and liver enzyme elevation were improved after stopping PTH. Accordingly, we report this case of an association between PTH and acute hepatitis.

keywords
Tuberculosis, Multidrug-Resistant, Hepatitis, Prothionamide

Reference

1.

1. The Korean Academy of Tuberculosis and Respiratory Diseases. The treatment guideline of tuberculosis. 4th ed. Seoul: The Korean Academy of Tuberculosis and Respiratory Diseases; 2005.

2.

2. Tostmann A, Boeree MJ, Aarnoutse RE, de Lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis druginduced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192-202.

3.

3. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006;11:699-707.

4.

4. Moon DS, Jang TW, Oak CH, Jung MH, Yoo CH, Song JY, et al. A case of pyrazinamide induced fulminant hepatic failure. Tuberc Respir Dis 2007;63:435-9.

5.

5. McElroy PD, Ijaz K, Lambert LA, Jereb JA, Iademarco MF, Castro KG, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005;41:1125-33.

6.

6. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272-6.

7.

7. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.

8.

8. Törün T, Güngör G, Ozmen I, Bölükbaşi Y, Maden E, Biçakçi B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005;9:1373-7.

9.

9. Furin JJ, Mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug- resistant tuberculosis. Int J Tuberc Lung Dis 2001;5:648-55.

10.

10. Bloss E, Kuksa L, Holtz TH, Riekstina V, Skripconoka V, Kammerer S, et al. Adverse events related to multidrug- resistant tuberculosis treatment, Latvia, 2000∼ 2004. Int J Tuberc Lung Dis 2010;14:275-81.

11.

11. Surucuoglu S, Ozkutuk N, Celik P, Gazi H, Dinc G, Kurutepe S, et al. Drug-resistant pulmonary tuberculosis in western Turkey: prevalence, clinical charac teristics and treatment outcome. Ann Saudi Med 2005; 25:313-8.

12.

12. Hyun JH, Kim JG, Jo SK, Yun IC. A case of toxic hepatitis induced prothionamide (TH-1321) and ethambutol. Korean J of Gastroenterol 1970;2:21-7.

13.

13. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603- 62.

14.

14. Marzuki OA, Fauzi AR, Ayoub S, Kamarul Imran M. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia. Singapore Med J 2008;49: 688-93.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy